Publication

Limits and challenges in using transport inhibitors to characterize how nano-sized drug carriers enter cells

Francia, V., Reker-Smit, C., Boel, G. & Salvati, A., 1-Jun-2019, In : Nanomedicine. 14, 12, p. 1533-1549 17 p.

Research output: Contribution to journalArticleAcademicpeer-review

APA

Francia, V., Reker-Smit, C., Boel, G., & Salvati, A. (2019). Limits and challenges in using transport inhibitors to characterize how nano-sized drug carriers enter cells. Nanomedicine, 14(12), 1533-1549. https://doi.org/10.2217/nnm-2018-0446

Author

Francia, Valentina ; Reker-Smit, Catharina ; Boel, Guido ; Salvati, Anna. / Limits and challenges in using transport inhibitors to characterize how nano-sized drug carriers enter cells. In: Nanomedicine. 2019 ; Vol. 14, No. 12. pp. 1533-1549.

Harvard

Francia, V, Reker-Smit, C, Boel, G & Salvati, A 2019, 'Limits and challenges in using transport inhibitors to characterize how nano-sized drug carriers enter cells', Nanomedicine, vol. 14, no. 12, pp. 1533-1549. https://doi.org/10.2217/nnm-2018-0446

Standard

Limits and challenges in using transport inhibitors to characterize how nano-sized drug carriers enter cells. / Francia, Valentina; Reker-Smit, Catharina; Boel, Guido; Salvati, Anna.

In: Nanomedicine, Vol. 14, No. 12, 01.06.2019, p. 1533-1549.

Research output: Contribution to journalArticleAcademicpeer-review

Vancouver

Francia V, Reker-Smit C, Boel G, Salvati A. Limits and challenges in using transport inhibitors to characterize how nano-sized drug carriers enter cells. Nanomedicine. 2019 Jun 1;14(12):1533-1549. https://doi.org/10.2217/nnm-2018-0446


BibTeX

@article{976f3c7951974339963c6356a5c9016c,
title = "Limits and challenges in using transport inhibitors to characterize how nano-sized drug carriers enter cells",
abstract = "Aim: In this work we illustrate limits and challenges associated with the use of pharmacological inhibitors to study how nanomedicines enter cells and show how such limits can be overcome. Materials & methods: We selected a panel of six common pharmacological inhibitors and a model nanoparticle-cell system. We tested eventual toxicity by measuring cell viability. We confirmed drug efficacy by measuring the uptake of control markers for the pathways involved by flow cytometry and fluorescence microscopy. Results & conclusion: We show how to optimize the use of pharmacological inhibitors and interpret the results generated. Furthermore, we demonstrate that some inhibitors cannot be used for nanomedicine studies because they lose their efficacy when serum is added, as required for nanoparticle exposure to cells.",
keywords = "drug carriers, drug delivery, endocytosis, flow cytometry, nanomedicine, nanoparticle uptake, silica nanoparticles, transport inhibitors, uptake pathways",
author = "Valentina Francia and Catharina Reker-Smit and Guido Boel and Anna Salvati",
year = "2019",
month = "6",
day = "1",
doi = "10.2217/nnm-2018-0446",
language = "English",
volume = "14",
pages = "1533--1549",
journal = "Nanomedicine",
issn = "1743-5889",
number = "12",

}

RIS

TY - JOUR

T1 - Limits and challenges in using transport inhibitors to characterize how nano-sized drug carriers enter cells

AU - Francia, Valentina

AU - Reker-Smit, Catharina

AU - Boel, Guido

AU - Salvati, Anna

PY - 2019/6/1

Y1 - 2019/6/1

N2 - Aim: In this work we illustrate limits and challenges associated with the use of pharmacological inhibitors to study how nanomedicines enter cells and show how such limits can be overcome. Materials & methods: We selected a panel of six common pharmacological inhibitors and a model nanoparticle-cell system. We tested eventual toxicity by measuring cell viability. We confirmed drug efficacy by measuring the uptake of control markers for the pathways involved by flow cytometry and fluorescence microscopy. Results & conclusion: We show how to optimize the use of pharmacological inhibitors and interpret the results generated. Furthermore, we demonstrate that some inhibitors cannot be used for nanomedicine studies because they lose their efficacy when serum is added, as required for nanoparticle exposure to cells.

AB - Aim: In this work we illustrate limits and challenges associated with the use of pharmacological inhibitors to study how nanomedicines enter cells and show how such limits can be overcome. Materials & methods: We selected a panel of six common pharmacological inhibitors and a model nanoparticle-cell system. We tested eventual toxicity by measuring cell viability. We confirmed drug efficacy by measuring the uptake of control markers for the pathways involved by flow cytometry and fluorescence microscopy. Results & conclusion: We show how to optimize the use of pharmacological inhibitors and interpret the results generated. Furthermore, we demonstrate that some inhibitors cannot be used for nanomedicine studies because they lose their efficacy when serum is added, as required for nanoparticle exposure to cells.

KW - drug carriers

KW - drug delivery

KW - endocytosis

KW - flow cytometry

KW - nanomedicine

KW - nanoparticle uptake

KW - silica nanoparticles

KW - transport inhibitors

KW - uptake pathways

UR - http://www.scopus.com/inward/record.url?scp=85068509020&partnerID=8YFLogxK

U2 - 10.2217/nnm-2018-0446

DO - 10.2217/nnm-2018-0446

M3 - Article

VL - 14

SP - 1533

EP - 1549

JO - Nanomedicine

JF - Nanomedicine

SN - 1743-5889

IS - 12

ER -

ID: 90916066